Menu
Back to Journals » Clinical Ophthalmology » Volume 4
Tolerability and effectiveness of preservative-free dorzolamide–timolol (preservative-free Cosopt®) in patients with open-angle glaucoma or ocular hypertension
Authors Hutnik C, Neima D, Ibrahim F, Scott R, Vaillancourt J, Haine D, Sampalis JS, Bastien N, Foucart S
Published 15 June 2010 Volume 2010:4 Pages 581—590
DOI https://doi.org/10.2147/OPTH.S10337
Review by Single anonymous peer review
Peer reviewer comments 3
Cindy Hutnik1, David Neima2, Fahim Ibrahim3, Robert Scott4, Julie Vaillancourt5, Denis Haine5, John S Sampalis5, Natacha Bastien6, Sylvain Foucart6
1Ivey Eye Institute, St Joseph Healthcare, London, Ontario, Canada; 2New Westminster, British Columbia, Canada; 3Point Edward, Ontario, Canada; 4Kentville, Nova Scotia, Canada; 5JSS Medical Research, Westmount, Quebec, Canada; 6Merck Frosst Canada Ltd, Kirkland, Quebec, Canada
Purpose: To assess the effect of preservative-free dorzolamide–timolol on nonvisual symptoms and intraocular pressure (IOP) in newly diagnosed and untreated patients with open-angle glaucoma or ocular hypertension.
Methods: This was a prospective, 8-week, open-label, Canadian multicenter study. All patients were treated with preservative-free dorzolamide–timolol formulation. The primary outcome was the change in the nonvisual symptom score of the Glaucoma Symptom Scale (GSS-SYMP-6) from baseline to 8 weeks. Secondary effectiveness outcome measures were absolute and percent changes in IOP from baseline to 4 and 8 weeks.
Results: One hundred and seventy-eight patients were enrolled. Mean (SD) age was 65.6 (12.1) years and 90 (50.6%) were females. There were 92 patients diagnosed with open-angle glaucoma, 62 with ocular hypertension, and 23 with both diseases (diagnosis was missing for one patient). The mean (SD) GSS-SYMP-6 score increased from 73.6 (21.8) at baseline to 76.1 (20.7) at 8 weeks (P = 0.097). Mean (SD) IOP significantly decreased by 11.7 (5.1) mmHg at 4 weeks (P < 0.001) and by 11.5 (5.3) mmHg at 8 weeks (P < 0.001), representing reductions of -38.5% (P < 0.001) and -38.0% (P < 0.001), respectively.
Conclusion: Preservative-free dorzolamide–timolol does not increase eye discomfort while significantly reducing IOP in patients with open-angle glaucoma or ocular-hypertension.
Keywords: open-angle glaucoma, ocular hypertension, GSS-SYMP-6, intraocular pressure, dorzolamide–timolol, preservative-free
© 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.